atai Life Sciences Announces Leadership Team Enhancements
New York and Berlin – atai Life Sciences (NASDAQ: ATAI), a pioneer in mental health therapeutics, has made strategic enhancements to its leadership team. Dr. Srinivas Rao, with over two decades of experience in biotechnology, steps up as the sole CEO. Joining him are newly promoted Kevin Craig, M.D. as Chief Medical Officer and Glenn Short, Ph.D. as Chief Scientific Officer. Gerd Kochendoerfer, Ph.D. also joins as the new Chief Operating Officer.
The leadership team’s expansion comes at a crucial time as atai advances VLS-01 and EMP-01 into Phase 2 clinical trials. These trials are significant for atai’s innovative approach in treating treatment-resistant depression and social anxiety disorder with next-generation psychedelics. The company anticipates key data from these trials in the coming years, aiming to revolutionize mental health care.
For further details, visit www.atai.life.
